Business Standard Indian drugmakers notch cleaner USFDA inspections as global outcomes worsen
USFDA data show OAI rates for Indian pharma plants falling to 8% by 2025 even as global outcomes worsen, reflecting stronger quality systems, technology adoption and compliance culture